AI주식인사이트AI Stock Insight
B

동구바이오제약

006620KOSDAQ

60.5 / 100

Reference Date: 2026-10-23

Financial Score33.0 / 40
News Sentiment12.5 / 25
Momentum8.0 / 20
Disclosure7.0 / 15
AI Analysis: PER is significantly undervalued vs. peers but Operating Profit is on a declining trend. Slightly down 5.0% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

DonggubioPharm operates diversified businesses including pharmaceutical manufacturing, new technology investments, marketing services, healthcare services, and pharmaceutical wholesale and consulting. In Q4 2024, its pharmaceutical segment achieved sales of 2,475 billion won, a 15.2% increase compared to the previous year. The company is expanding into new sectors such as biotech investments and medical tourism to enhance growth potential.

Number of Employees

440people

Average Salary

56.5M KRW

Score Calculation Basis

Detailed Financial Score

PER
1.80Industry Average 15.008.0Point

Half of industry avg (excellent)

PBR
0.63Industry Average 1.205.5Point

Lower than industry avg (good)

ROE
38.95Industry Average 8.007.0Point

4.9x industry avg (excellent)

Debt Ratio
30.70Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points
Revenue Growth Rate
2.0 / 3

Avg ▲6.5% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼20.1% (2-year basis)

ROE Trend
4.0 / 4

Avg ROE 17.3% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 3,345Won52-week high 6,09052-week low 3,340
1-month return2.0Point

1m -4.97% (slight drop)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

4 totalPositive 0Neutral 3Negative 1
  • Neutral신탁계약에의한취득상황보고서2026-10-22
  • Neutral주식등의대량보유상황보고서(일반)2026-10-19
  • Negative[기재정정]주요사항보고서(영업정지)2026-10-08
  • Neutral주식등의대량보유상황보고서(일반)2026-10-08